CAJ | 학술논문

目的评价吉西他滨联合顺铂(GP方案)与长春瑞滨联合顺铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法 85例晚期NSCLC患者采用完全随机法分为GP组42例和NP组43例.分别用GP方案和NP方案化疗2个周期后对2组的临床疗效和不良反应进行评价.结果 GP组有效率为40.5%,NP组为39.5%,2组间比较差异无统计学意义(P>0.05).2组不良反应主要为骨髓抑制,GP组血小板减少高于NP组(P<0.05),NP组白细胞下降高于GP组(P<0.05),均可耐受.结论吉西他滨或长春瑞滨联合顺铂治疗晚期NSCLC具有较好的耐受性和临床疗效,不良反应有所不同,但都可以耐受.
목적 평개길서타빈연합순박(GP방안)여장춘서빈연합순박(NP방안)치료만기비소세포폐암(NSCLC)적료효화불량반응.방법 85례만기NSCLC환자채용완전수궤법분위GP조42례화NP조43례.분별용GP방안화NP방안화료2개주기후대2조적림상료효화불량반응진행평개.결과 GP조유효솔위40.5%,NP조위39.5%,2조간비교차이무통계학의의(P>0.05).2조불량반응주요위골수억제,GP조혈소판감소고우NP조(P<0.05),NP조백세포하강고우GP조(P<0.05),균가내수.결론 길서타빈혹장춘서빈연합순박치료만기NSCLC구유교호적내수성화림상료효,불량반응유소불동,단도가이내수.
Objective To evaluate side effects of gemcitabine plus cisplation (GP Programme) therapy and navelbine plus cisplation (NP programme) therapy for non-small cell lung cancer (NSCLC). Methods Eight-five advanced non-small cell lung cancer patients were divided into 2 groups: 42 with GP and 43 with NP. Results The response rates of GP and NP group were 40.5% and 39.5% respectively. There was no significant difference in response rate between the two groups (P>0.05). The major adverse reactions were myelosuppression. Thrombocytopenia in GP Group was higher than NP group, leukopenia in NP Group was higher than GP group. Conclusion Both GP and NP regimens are effective for advanced NSCLC. The side effects of the two regimens are different but all adverse reactions are tolerable.